New £30 Million Fund Launched to Find a Cure for Myeloma, a Type of Blood Cancer

A new fund worth £30 million is being created to speed up the development of treatments, tests, and technologies that could one day cure myeloma. Myeloma is a type of blood cancer that currently has no cure, and it takes the lives of eight people every day in the UK alone. The fund, called the Jacquelin Forbes-Nixon Myeloma Fund, is being set up by the DFN Foundation, which has already secured £15 million. This includes £10 million from the foundation itself and £5 million from philanthropist and investor David Forbes-Nixon OBE, but only if other donors also contribute an equal amount. The fund will look for another £15 million from other charitable partners and will focus on supporting early-stage scientific and medical research projects that may be too risky or too new for regular investors to support. Unlike traditional charity donations, this fund will invest money into promising projects and use any profits made to fund future research, creating a sustainable cycle of innovation. This initiative is part of the larger Jacquelin Forbes-Nixon Myeloma Mission, which aims to find a functional cure for more patients over the next ten years and beyond. Myeloma starts in the bone marrow and affects around 16 people every day in the UK. It can be hard to diagnose, with about one-third of patients only finding out they have it after an emergency visit to the hospital. David Forbes-Nixon OBE, the founder and Chairman of the DFN Foundation and the JFN Myeloma Fund, shared his motivation: ‘When my mother Jacquelin passed away from myeloma, I promised her I would do everything possible to find a cure.’ He explained that while science has made huge progress in the last 20 years, many promising ideas still struggle to get funding because they are seen as too early or too risky. ‘That’s why the DFN Foundation is contributing £10 million, and I’m personally adding £5 million,’ he said. ‘Now, we’re asking others to match our commitment and help us reach the £30 million goal.’ Dr. Stephanie Oestreich, the Managing Director of the JFN Myeloma Fund, added: ‘There is amazing science happening in myeloma research, but great science doesn’t always turn into treatments.’ She emphasized that the real measure of success will be how quickly better treatments can reach patients, and that’s exactly what this fund aims to achieve.

Leave a Comment

Scroll to Top